Aug 11, 2020
Cardiff Oncology Announces Second Quarter 2020 Results and Highlights
Jun 19, 2020
Innovent Announces the NMPA Granted Marketing Approval for BYVASDA® (Bevacizumab Biosimilar) in China
Jun 16, 2020
Oncologie Announces Key Updates and Planned Activities for its Clinical Programs and RNA-based Biomarker Platform
Jun 12, 2020
EHA25Virtual: A Safe and Strikingly Effective Biologic Therapy for the World's Second Most Common Hereditary Bleeding Disorder
Jun 09, 2020
Cardiff Oncology Announces Expanded Access Program for Onvansertib in KRAS-Mutated Metastatic Colorectal Cancer as Follow-On to Fast Track Designation
May 31, 2020
Innovent Biologics Announced the Results of the Phase 1b Clinical Study of TYVYT® (Sintilimab Injection) in Combination with IBI305 (Bevacizumab Biosimilar) in the Treatment of Advanced Hepatocellular Carcinoma
May 29, 2020
PathAI Demonstrates the Potential of AI-based Characterization of the Tumor Microenvironment at ASCO
May 29, 2020
Cardiff Oncology Data Continues to Demonstrate Efficacy of Onvansertib in Patients with KRAS-Mutated Metastatic Colorectal Cancer Presented at ASCO
May 28, 2020
Cardiff Oncology Announces Fast Track Designation Granted by the FDA to Onvansertib for Second-Line Treatment of KRAS-Mutated Colorectal Cancer
May 13, 2020
Cardiff Oncology Enters Agreement with PoC Capital to Fund Phase 2 Clinical Trial of Onvansertib in KRAS-Mutated Metastatic Colorectal Cancer (mCRC)
Apr 01, 2020
Trovagene Announces Acceptance of Phase 1b/2 KRAS-Mutated Metastatic Colorectal Cancer (mCRC) Trial Abstract for Presentation at the 2020 ASCO Annual Meeting
Mar 31, 2020
Caris Life Sciences Launches MI FOLFOXai, Improving Overall Survival by 50% for Metastatic Colorectal Cancer Patients
Mar 30, 2020
Innovent Announces Financial Results for Full Year Ended December 31, 2019 and Corporate Progress
Mar 09, 2020
U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Bevacizumab for Review
Feb 24, 2020
Top 10 Cancer Drugs Market Study, 2018-2026 - Keytruda Anticipated to Grow at the Highest Rate
Feb 24, 2020
U.S. FDA accepts GSK's sNDA application for Zejula (niraparib) for first-line maintenance treatment for women with platinum-responsive advanced ovarian cancer
Feb 18, 2020
The First Patient Included in Japan in Isofol's Phase 3 AGENT Study
Jan 21, 2020
Trovagene to Present New Clinical Data for Onvansertib in Metastatic KRAS-Mutated Colorectal Cancer at ASCO 2020 Gastrointestinal Cancers Symposium
Jan 13, 2020
Mereo BioPharma and Oncologie Enter into Global Licensing Agreement for Navicixizumab
Dec 24, 2019
The global colorectal cancer market is expected to reach US$ 22,953.8 Mn in 2027 from US$ 16,339.9 Mn in 2018